Prevention of premenstrual exacerbation of hereditary coproporphyria by gonadotropin-releasing hormone analogue.
A 20-year-old Japanese female needed frequent hospitalization due to premenstrual exacerbation of hereditary coproporphyria (HCP). Intranasal buserelin acetate, a gonadotropin-releasing hormone analogue, was given to suppress her menstrual cycles. Her porphyric symptoms subsided dramatically as she became amenorrhoeic. Urinary excretion of porphyrin derivatives fell significantly. She has been free from recurrent attacks, but suffers a minor porphyric attack once in 5 years. However, borderline osteopenia secondary to hypoestrogenism has been noted. Although these analogues are potent in suppressing estrogen-induced porphyric symptoms, due precautions should be taken to avoid bone demineralization in the long-term use.
Yamamori
I
I
Department of Internal Medicine, the Japanese Red Cross Nagoya First Hospital.
Asai
M
M
Tanaka
F
F
Muramoto
A
A
Hasegawa
H
H
D000328:Adult; D001851:Bone Diseases, Metabolic / Q000139:chemically induced; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D007564:Japan; D008597:Menstrual Cycle / Q000187:drug effects*; D011164:Porphyrias / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control*; D011166:Porphyrins / Q000652:urine
D004967:Estrogens; D011166:Porphyrins; D002064:Buserelin